Archives For Drug Development

This week, over 400,000 people ranging from different backgrounds will come together to attend an event that has an impact on all of our lives.  This event is the Healthcare Information and Management Systems Society Conference of 2016 or in twitter lingo, #HIMSS16

You might be thinking, why does this effect me? No, it’s not because quarterback Peyton Manning will be attending as a keynote.  It’s because HIMSS16 revolves around leveraging IT to better healthcare.  Everyone has experienced a bump in the road or negative experience when it comes to healthcare.  We are all looking for that next big thing to improve these issues.  Having a week of keynotes, panels, meet-ups, showcases, etc. that are dedicated to healthcare innovation, is the perfect place to start conversations about these problems and brainstorm how to go about solving them.  

5 questions causing buzz at HIMSS16:

1.) How can we leverage IT to better healthcare?

This is the overarching question of the whole conference.  Whether you are an attendee that is a physician, data scientist, or representing a vendor, you are attending to better healthcare in some way.  Our team is always looking to use data in different ways to assist in healthcare decisions.  We are optimistic that more data will become open and available to consume. Continue Reading…

This datacard uses the Medicare Part D Database to identify top prescribers and top to prescribing geographies of drugs.

14_5M_claims_related_to_146_926_Healthcare_Providers___karmadata

Entities include: physicians, drugs

Purpose: market research, clinical operations

 

EMA drug approvals

We recently added the European public assessment reports (EPAR) data set.  Here is a rank of non-generic EMA product approvals since 2009 by company.

Orphan Drug Designations

Orphan drugs have been a hot topic of late.  We created this card which shows a steady increase in the number of companies receiving orphan drug designations from the FDA.